Published in Infect Immun on May 01, 1982
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Clostridial enteric diseases of domestic animals. Clin Microbiol Rev (1996) 4.97
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Serogrouping of Clostridium difficile strains by slide agglutination. J Clin Microbiol (1985) 3.06
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev (1993) 2.19
Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect Immun (1987) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut (1986) 1.93
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun (1994) 1.68
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun (1998) 1.63
Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun (1983) 1.51
Modulation of cytotoxin production by Clostridium difficile in the intestinal tracts of gnotobiotic mice inoculated with various human intestinal bacteria. Appl Environ Microbiol (1985) 1.47
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
Biochemical studies on the effect of Clostridium difficile toxin B on actin in vivo and in vitro. Infect Immun (1987) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother (1996) 1.17
Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Can J Infect Dis (2004) 1.16
Enterotoxins from Clostridium difficile; diarrhoeogenic potency and morphological effects in the rat intestine. Gut (1990) 1.15
Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect Immun (2011) 1.09
A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine (2009) 1.08
Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. PLoS Pathog (2013) 1.08
Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother (1997) 1.07
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice. Infect Immun (2007) 1.06
A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (2013) 1.02
In vivo physiological and transcriptional profiling reveals host responses to Clostridium difficile toxin A and toxin B. Infect Immun (2013) 0.98
The host immune response to Clostridium difficile infection. Ther Adv Infect Dis (2013) 0.96
Emergence in gnotobiotic mice of nontoxinogenic clones of Clostridium difficile from a toxinogenic one. Infect Immun (1988) 0.94
Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun (2013) 0.94
TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. Mol Microbiol (2012) 0.93
Effect of Clostridium difficile enterotoxin A on ultrastructure of Chinese hamster ovary cells. Infect Immun (1989) 0.91
Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol (2014) 0.87
High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types. BMC Microbiol (2015) 0.78
Enzyme immunoassay for detection of antibody to toxins A and B of Clostridium difficile. J Clin Microbiol (1983) 0.76
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Selective and differential medium for isolation of Clostridium difficile. J Clin Microbiol (1979) 12.54
Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet (1978) 11.99
Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J (1978) 8.47
Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis (1977) 7.68
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J (1978) 4.99
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Pseudomembranous colitis: Presence of clostridial toxin. Lancet (1978) 4.30
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Clinical and laboratory observations in Clostridium difficile colitis. Am J Clin Nutr (1980) 3.89
Oral vancomycin for antibiotic-associated pseudomembranous colitis. Lancet (1978) 2.87
Purification and characterization of Clostridium difficile toxin. Infect Immun (1979) 2.71
Clindamycin-induced enterocolitis in hamsters. J Infect Dis (1978) 2.43
Partial purification and characterization of a cytotoxin from Clostridium difficile. Rev Infect Dis (1980) 2.31
Fatal enterocolitis in hamsters given lincomycin hydrochloride. Lab Anim Care (1968) 2.17
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
Special features of the priming process for a secretory IgA response. B cell priming with cholera toxin. J Exp Med (1981) 2.00
Prevention of clindamycin-induced colitis in hamsters by Clostridium sordellii antitoxin. Gastroenterology (1979) 1.80
Clindamycin-associated colitis in hamsters: protection with vancomycin. Gastroenterology (1977) 1.20
Immunological control mechanism against cholera toxin: interference with toxin binding to intestinal receptors. Infect Immun (1976) 1.17
Light and electron microscopic studies of antibiotic associated colitis in the hamster. Gut (1979) 1.08
Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1976) 9.38
Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria. Antimicrob Agents Chemother (1973) 9.35
Fermentation of mucin and plant polysaccharides by strains of Bacteroides from the human colon. Appl Environ Microbiol (1977) 8.29
Clostridium difficile: its disease and toxins. Clin Microbiol Rev (1988) 7.26
Purification and characterization of toxins A and B of Clostridium difficile. Infect Immun (1982) 6.88
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Collaborative evaluation of a proposed reference dilution method of susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1979) 5.10
Biological activities of toxins A and B of Clostridium difficile. Infect Immun (1982) 4.62
Development of a micromethod for identification of anaerobic bacteria. Appl Microbiol (1975) 4.58
Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl Environ Microbiol (1977) 4.09
Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun (1990) 4.06
Production of Clostridium difficile antitoxin. Infect Immun (1980) 3.95
Micromethod for identification of anaerobic bacteria: design and operation of apparatus. Appl Microbiol (1975) 3.80
Enzyme-linked immunosorbent assay for Clostridium difficile toxin A. J Clin Microbiol (1983) 3.40
Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res (1990) 2.93
Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1-4GlcNAc. Infect Immun (1986) 2.89
Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol (1982) 2.86
Arginine, a growth-limiting factor for Eubacterium lentum. J Bacteriol (1976) 2.67
Production by Salmonella typhimurium of 2,3-dihydroxybenzoylserine, and its stimulation of growth in human serum. J Infect Dis (1970) 2.62
Vacuolation of sensory ganglion neuron cytoplasm in rats with long-term exposure to organophosphates. Toxicol Pathol (2010) 2.53
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile. Infect Immun (1992) 2.49
Medium-dependent inhibition of Peptostreptococcus anaerobius by sodium polyanetholsulfonate in blood culture media. J Clin Microbiol (1976) 2.46
Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol (1985) 2.46
Production of antitoxins to two toxins of Clostridium difficile and immunological comparison of the toxins by cross-neutralization studies. Infect Immun (1982) 2.14
The enterotoxin of Bacteroides fragilis is a metalloprotease. Infect Immun (1995) 2.06
Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun (1986) 2.01
Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect Immun (1988) 2.00
Purification and characterization of an enterotoxin from Bacteroides fragilis. Infect Immun (1992) 1.97
Commercial latex test for Clostridium difficile toxin A does not detect toxin A. J Clin Microbiol (1986) 1.92
Differential effects of Clostridium difficile toxins on tissue-cultured cells. J Clin Microbiol (1982) 1.87
Resistance of some species of Clostridium to clindamycin. Antimicrob Agents Chemother (1973) 1.81
Effect of clavulanic Acid on anaerobic bacteria resistant to Beta-lactam antibiotics. Antimicrob Agents Chemother (1978) 1.78
In vivo protection of Fusobacterium necrophorum from penicillin by Bacteroides fragilis. Antimicrob Agents Chemother (1975) 1.78
Problems associated with counterimmunoelectrophoresis assays for detecting Clostridium difficile toxin. J Clin Microbiol (1982) 1.75
Chemotherapy of an experimental Fusobacterium (Sphaerophorus) necrophorum infection in mice. Antimicrob Agents Chemother (1974) 1.71
Identification of the latex test-reactive protein of Clostridium difficile as glutamate dehydrogenase. J Clin Microbiol (1991) 1.67
Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun (1991) 1.66
Fibrinolytic activity of oral anaerobic bacteria. Arch Oral Biol (1978) 1.65
Toxin A of Clostridium difficile is a potent cytotoxin. J Clin Microbiol (1990) 1.65
Use of semisolid agar from initiation of pure Bacteroides fragilis infection in mice. Infect Immun (1976) 1.64
Bacteroides fragilis enterotoxin modulates epithelial permeability and bacterial internalization by HT-29 enterocytes. Gastroenterology (1996) 1.63
Inhibition of Bacteroides fragilis on blood agar plates and reversal of inhibition by added hemin. J Clin Microbiol (1976) 1.63
Beta-Lactamase activity in strains of Bacteroides melaninogenicus and Bacteroides oralis. Antimicrob Agents Chemother (1977) 1.62
Laminarinase (beta-glucanase) activity in Bacteroides from the human colon. Appl Environ Microbiol (1977) 1.61
Proteolytic activity of the Bacteroides fragilis enterotoxin causes fluid secretion and intestinal damage in vivo. Infect Immun (1995) 1.59
Purification of Clostridium difficile toxin A by affinity chromatography on immobilized thyroglobulin. Infect Immun (1987) 1.57
Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect Immun (1986) 1.57
Requirement of heme for growth of Bacteroides fragilis. Appl Environ Microbiol (1977) 1.53
Clostridium difficile toxin A in infants. J Infect Dis (1983) 1.53
Toxin A from Clostridium difficile binds to rabbit erythrocyte glycolipids with terminal Gal alpha 1-3Gal beta 1-4GlcNAc sequences. Arch Biochem Biophys (1987) 1.51
Vaspar broth-disk procedure for antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother (1980) 1.50
Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect Immun (1987) 1.47
Comparison of Clostridium sordellii toxins HT and LT with toxins A and B of C. difficile. J Med Microbiol (1992) 1.47
The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells. Infect Immun (1997) 1.46
Cytochrome spectrum of an obligate anaerobe, Eubacterium lentum. J Bacteriol (1976) 1.45
Bacteriophages of Bacteroides. Rev Infect Dis (1980) 1.44
Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun (1991) 1.44
Clostridium perfringens iota toxin: synergism between two proteins. Toxicon (1986) 1.43
Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun (1991) 1.42
Cholesterol-reducing bacterium from human feces. Appl Environ Microbiol (1977) 1.40
Purification and characterization of Clostridium sordellii hemorrhagic toxin and cross-reactivity with Clostridium difficile toxin A (enterotoxin). Infect Immun (1988) 1.40
Influence of pencillinase production by strains of Bacteroides melaninogenicus and Bacteriodes oralis on pencillin therapy of an experimental mixed anaerobic infection in mice. Arch Oral Biol (1976) 1.39
Cloning and characterization of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol Lett (1997) 1.36
Characterization of cross-reactive proteins detected by Culturette Brand Rapid Latex Test for Clostridium difficile. J Clin Microbiol (1988) 1.34
Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for toxin A and toxin B in the diagnosis of Clostridium difficile-related enteric disease. Diagn Microbiol Infect Dis (1986) 1.34
Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun (1992) 1.32
Susceptibility of anaerobic bacteria to sulfamethoxazole/trimethoprim and routine susceptibility testing. Antimicrob Agents Chemother (1978) 1.26
Rabbit sucrase-isomaltase contains a functional intestinal receptor for Clostridium difficile toxin A. J Clin Invest (1996) 1.26
Isolation of auxotrophs of Bacteroides fragilis. Can J Microbiol (1978) 1.21
High-level expression of a heterologous protein in the milk of transgenic swine using the cDNA encoding human protein C. Proc Natl Acad Sci U S A (1992) 1.20
Feline lipidosis. Light and electron microscopic studies. Arch Pathol (1971) 1.20
Positive regulation of Clostridium difficile toxins. Infect Immun (1997) 1.17
Bacteriocin production by strains of Bacteroides isolated from human feces and the role of these strains in the bacterial ecology of the colon. Antimicrob Agents Chemother (1977) 1.16
Mutagenesis of the Clostridium difficile toxin B gene and effect on cytotoxic activity. Microb Pathog (1994) 1.14
TechLab and alexon Giardia enzyme-linked immunosorbent assay kits detect cyst wall protein 1. J Clin Microbiol (1999) 1.13
Methods to identify and characterize developmental neurotoxicity for human health risk assessment. II: neuropathology. Environ Health Perspect (2001) 1.13
Role of Clostridium difficile toxins in disease. Gastroenterology (1987) 1.11
The fecapentaenes, potent mutagens from human feces. Chem Res Toxicol (1992) 1.11
Carbohydrate repression of catalase synthesis in Bacteroides fragilis. J Bacteriol (1977) 1.11
Effect of high-fiber and high-oil diets on the fecal flora of swine. Appl Environ Microbiol (1987) 1.10
Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect Immun (1989) 1.09
Degradation of polysaccharides by intestinal bacterial enzymes. Am J Clin Nutr (1978) 1.07
Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis. Infect Immun (1998) 1.06
Transparent plastic incubator for the anaerobic glove box. Appl Environ Microbiol (1977) 1.06
The neuropathology of globoid-cell leucodystrophy in the dog. A report of two cases. Acta Neuropathol (1968) 1.04
Characterization of enterotoxigenic Bacteroides fragilis by a toxin-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (1994) 1.04
Breakdown of psyllium hydrocolloid by strains of Bacterioides ovatus from the human intestinal tract. Can J Microbiol (1978) 1.04
Human chorionic gonadotropin detected in urinary concentrates from patients with malignant tumors of the testis, prostate, bladder, ureter and kidney. J Urol (1983) 1.03
Comparison of cefoxitin and cephalothin therapy of a mixed Bacteroides fragilis and Fusobacterius necrophorum infection in mice. Antimicrob Agents Chemother (1975) 1.03
Chemotherapy of an experimental Bacteroides fragilis infection in mice. Antimicrob Agents Chemother (1977) 1.01
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Two patterns of neutral steroid conversion in the feces of normal North Americans. Cancer Res (1974) 1.00
Rapid death of infant rhesus monkeys injected with Clostridium difficile toxins A and B: physiologic and pathologic basis. J Pediatr (1984) 1.00
Anaerobic specimen transport device. J Clin Microbiol (1975) 0.99
Cytotoxicity of Clostridium difficile toxin A for human colonic and pancreatic carcinoma cell lines. Cancer Res (1992) 0.98
Production of antisera against the enterotoxin of Bacteroides fragilis and their use in a cytotoxicity neutralization assay of HT-29 cells. Clin Diagn Lab Immunol (1994) 0.98
Construction and expression of the complete Clostridium difficile toxin A gene in Escherichia coli. Infect Immun (1991) 0.96